 | • レポートコード：B-MOR-040412 • 出版社/出版日：Mordor Intelligence / 2018年3月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、抗ウイルス治療薬の世界市場について調べ、抗ウイルス治療薬の世界規模、市場動向、市場環境、薬剤タイプ別（ヘルペス、肝炎、HIV、インフルエンザ、その他）分析、販売チャネル別（院内薬局、独立型薬局・ドラッグストア、オンライン薬局）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・抗ウイルス治療薬の世界市場インサイト ・抗ウイルス治療薬の世界市場環境 ・抗ウイルス治療薬の世界市場動向 ・抗ウイルス治療薬の世界市場規模 ・抗ウイルス治療薬の世界市場規模：薬剤タイプ別（ヘルペス、肝炎、HIV、インフルエンザ、その他） ・抗ウイルス治療薬の世界市場規模：販売チャネル別（院内薬局、独立型薬局・ドラッグストア、オンライン薬局） ・抗ウイルス治療薬の世界市場：地域別市場規模・分析 ・抗ウイルス治療薬の北米市場規模・予測 ・抗ウイルス治療薬のアメリカ市場規模・予測 ・抗ウイルス治療薬のヨーロッパ市場規模・予測 ・抗ウイルス治療薬のアジア市場規模・予測 ・抗ウイルス治療薬の日本市場規模・予測 ・抗ウイルス治療薬の中国市場規模・予測 ・抗ウイルス治療薬のインド市場規模・予測 ・抗ウイルス治療薬の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global anti-viral Therapeutics market is expected to register a CAGR of 6.2% during the forecast period, 2018 to 2023. North America dominates the market due to growing prevalence of Hepatitis C & HIV infections, coupled with the presence of huge patient pool suffering from virally infectious diseases.
High Prevalence of Different Viral Infection
According to the World Health Organization (WHO), it is estimated that in 2015, nearly 36.7 million individuals had HIV. It has been identified that most of this prevalence is in low and middle-income countries. According to UNAIDS in 2016, around 1.8 million people with new HIV infection were reported worldwide. In 2017, 20.9 million people were accessing antiretroviral therapy, globally. The huge patient pool indicates high demand for anti-viral drugs, which will likely drive the market growth during the forecast period.Other factors that drive the market include increasing initiatives by public and private companies, advancements in molecular biology promoting drug development, and a strong pipeline for antiviral drugs.
Therapeutics Going Off-patent
Therapeutics losing patent exclusivity affects the market largely. Along with the innovator company, there are many regional/local players in the market. Due to this, the prices of the Therapeutics come down rapidly and the overall market gets affected. In the year 2016 itself, quite a few HIV Therapeutics had gone off-patent. Epzicom, Trizivir, Norvir, and Kaletra lost patent exclusivity in 2016. Abbott’s Kaletra has more than 8% share in the HIV anti-virals market. This will greatly affect the market for anti-viral drugs.The high cost of anti-viral drug treatment also hinders the growth of the market.
North America to Dominate the Market
North America dominates the global anti-viral Therapeutics market owing to the presence of well-established market players, and growing prevalence of HIV and Hepatitis C infections. Asia-Pacific is expected to grow tremendously during the forecast period owing to factors, such as high prevalence of HIV infection, growing awareness regarding HIV infection, and increasing collaboration between public and private sectors to provide affordable treatment to the low and middle-income countries.
Key Developments in the Market
• February 2018: Gilead Sciences Inc received approval from US Food and Drug Administration (FDA), for Biktarvy, a daily single tablet regimen (STR) for the treatment of HIV-1 infection.
• August 2017: AbbVie received approval from US Food and Drug Administration, for MAVYRET (glecaprevir/pibrentasvir), treatment for adults with chronic hepatitis C virus (HCV) infection.
Major Players: ABBVIE, INC., BRISTOL-MEYRS SQUIBB COMPANY, CIPLA, INC., F. HOFFMANN-LA ROCHE LTD., GILEAD SCIENCES INC, GLAXOSMITHKLINE PLC, MERCK & CO., INC., PFIZER INC., SANOFI, AND JOHNSON & JOHNSON, amongst others.
Reasons to Purchase this Report
• Current and future global anti-viral therapeutics market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players
• 3 months analyst support along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Initiatives by Public and Private Companies
6.1.2 Advancements in Molecular Biology Promoting Drug Development
6.1.3 Rising Prevalence of HIV Infection
6.1.4 Strong Pipeline for Antiviral Drugs
6.2 Market Restraints
6.2.1 Drugs going off-Patent
6.2.2 High Cost of Antiviral Drug Treatment
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation -By Drug Type
7.1.1 Herpes Antiviral Drugs
7.1.1.1 Valacyclovir
7.1.1.2 Acyclovir
7.1.1.3 Famciclovir
7.1.2 Hepatitis Antiviral Drugs
7.1.2.1 Peginterferon
7.1.2.2 Entecavir
7.1.3 HIV Antiviral Drugs
7.1.3.1 Emtricitabine and Tenofovir disoproxil fumarate
7.1.3.2 Atazanavir
7.1.3.3 Lopinavir & Ritonavir
7.1.3.4 Abacavir & lamivudine
7.1.3.5 Darunavir
7.1.3.6 Lamivudine & Zidovudine
7.1.3.7 Raltegravir
7.1.4 Influenza Antiviral Drugs
7.1.4.1 Oseltamivir phosphate
7.1.4.2 Zanamivir
7.1.4.3 Peramivir
7.1.5 Others Antiviral Drugs
7.2 Segmentation -By Distribution Channel
7.2.1 Hospital Pharmacy
7.2.2 Independent Pharmacy and Drug Store
7.2.3 Online Pharmacy
7.3 Segmentation – by Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest Of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 AbbVie, Inc.
9.2 Bristol-Meyrs Squibb Company
9.3 Cipla, Inc.
9.4 F. Hoffmann-La Roche Ltd.
9.5 Gilead Sciences Inc
9.6 GlaxoSmithKline plc
9.7 Johnson & Johnson
9.8 Merck & Co., Inc.
9.9 Pfizer Inc.
9.10 Sanofi
9.11 Others
10. Future of the Market